Novo Nordisk A/S (NYSE:NVO) Shares Sold by Capital Market Strategies LLC

Capital Market Strategies LLC cut its holdings in Novo Nordisk A/S (NYSE:NVO) by 38.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,097 shares of the company’s stock after selling 3,797 shares during the period. Capital Market Strategies LLC’s holdings in Novo Nordisk A/S were worth $524,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also made changes to their positions in the business. Strategic Investment Solutions Inc. IL acquired a new position in Novo Nordisk A/S in the second quarter valued at $25,000. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the 3rd quarter valued at about $28,000. Abound Wealth Management grew its stake in Novo Nordisk A/S by 257.4% during the 2nd quarter. Abound Wealth Management now owns 218 shares of the company’s stock worth $31,000 after buying an additional 157 shares during the last quarter. Capital Performance Advisors LLP acquired a new position in Novo Nordisk A/S during the third quarter worth approximately $42,000. Finally, Carolina Wealth Advisors LLC acquired a new stake in shares of Novo Nordisk A/S in the third quarter valued at approximately $48,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts have recently commented on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday. BMO Capital Markets dropped their price target on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research note on Sunday, December 29th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $140.20.

Novo Nordisk A/S Stock Performance

Shares of NVO stock traded down $2.39 during trading hours on Monday, reaching $85.26. 5,344,828 shares of the company’s stock were exchanged, compared to its average volume of 4,406,944. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1 year low of $81.50 and a 1 year high of $148.15. The company has a market cap of $382.61 billion, a P/E ratio of 27.59, a price-to-earnings-growth ratio of 1.37 and a beta of 0.45. The company’s 50 day moving average is $103.06 and its two-hundred day moving average is $121.08.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.